4th 2021 quarter turnover rise of 26% consistent with the annual revenue growth by 27%
January 18 2022 - 11:00AM
4th 2021 quarter turnover rise of 26% consistent with the annual
revenue growth by 27%
Press Release
Ecully,
18
January,
2021 – 6 pm
Revenue increased by 27% in 2021 to
€4.3 MQ4
2021 superior to Q4
2020 (+
26%)
In thousands of euros |
2021* |
2020 |
% Variation |
Q1 Revenue |
864 |
1 039 |
- 17% |
Q2 Revenue |
1 021 |
404 |
+ 153% |
Q3 Revenue |
1 060 |
868 |
+ 22% |
Q4 Revenue |
1 345 |
1 067 |
+ 26% |
Annual Revenue |
4 290 |
3 379 |
+ 27% |
*Figures not audited including revenue from
Distimp since its acquisition date, i.e., from 26 June 2021 through
31 December 2021, representing 365 k€.
In a context still disrupted by the
pandemic, Spineway closes the
2021 financial year with a turnover of €4.3 million, up 27%
compared to 2020, driven by a strong commercial dynamic concretized
by a 4th quarter at €1.3 million, up 26% compared to last
year.
This growth was driven
in particular by high sales
performances in the Group's
historical areas. Thus, Latin America
recorded revenues of nearly €2 million, up 33% compared to fiscal
year 2020, despite a still complicated situation; while sales in
Asia reached €1 million, up 19% compared to
2020.
Moreover, in line with its strategy, Spineway is
continuing to develop its product mix by strengthening its higher
value-added ranges. Thus, benefiting from the first commercial
synergies with Distimp, sales in Europe amounted
to nearly €1 million, up 38% compared to last year.
The financial situation remains very solid and
reinforces the Group's capacity to accelerate its development
through investments.
After a strong fourth quarter,
Spineway is pursuing its strategic plan
combining organic and external growth with the ambition of becoming
a leading European player with premium positioning in spine
surgery.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME
(EQUITY SAVINGS PLANS FOR SMES)Find out all about Spineway
at www.spineway.com
This press release has been prepared in both
English and French. In case of discrepancies, the French version
shall prevail.
Spineway designs, manufactures and markets
innovative implants and surgical instruments for treating severe
disorders of the spinal column.Spineway
has an international network of over 50 independent
distributors and 90% of its revenue comes from
exports.Spineway, which is
eligible for investment through FCPIs (French unit trusts
specializing in innovation), has received the OSEO Excellence award
since 2011 and has won the Deloitte Fast 50 award (2011). Rhône
Alpes INPI Patent Innovation award (2013) – INPI Talent award
(2015). ISIN: FR0011398874 - ALSPW
Contacts:
SPINEWAYShareholder-services lineAvailable Tuesday
through Thursday+33 (0)806 706 060 |
Eligible PEA / PMEALSPWEuronext Growth |
AELIUM Finance & CommunicationInvestor
relationsSolène Kennisspineway@aelium.fr |
Spineway (EU:ALSPW)
Historical Stock Chart
From Oct 2024 to Oct 2024
Spineway (EU:ALSPW)
Historical Stock Chart
From Oct 2023 to Oct 2024